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Background: Copeptin, the C-terminal moiety of provasopressin, is cosecreted with vasopressin.
Copeptin may be a useful parameter to characterize disorders of water homeostasis and can be
readilymeasured inplasmaor serum.However, it is unknown todatehowcirculating copeptin and
vasopressin levels correlate at different plasma osmolalites.
Objective: To correlate plasma copeptin with plasma osmolality and vasopressin concentrations in
healthy subjects during iso-, hypo-, and hyperosmolar states.
Methods: Plasma osmolalities, copeptin, and vasopressin levels weremeasured in 20 volunteers at
baseline, after an oral water load, and during and after iv infusion of 3% saline. Correlation
coefficients were determined between plasma osmolalites and copeptin and vasopressin concen-
trations, as well as between vasopressin and copeptin concentrations.
Results:Median plasma osmolalities decreased from 290mOsm/kg (range, 284–302) at baseline to
281 (273–288) mOsm/kg after water load and rose to 301 (298–307) mOsm/kg after hypertonic
saline.Median plasma copeptin concentrations decreased from 3.3 (1.1–36.4) pM at baseline to 2.0
(0.9–10.4) pM after water load and increased to 13.6 (3.7–43.3) pM after hypertonic saline. Vaso-
pressin and copeptin concentrations correlated with plasma osmolality (Spearman’s rank corre-
lation coefficient 0.49 and 0.77, respectively). There was a close correlation of vasopressin and
copeptin concentrations (Spearman’s rank correlation coefficient 0.8).
Conclusion: Plasma vasopressin and copeptin correlate strongly over a wide range of osmolalities
in healthy individuals. Therefore, the measurement of copeptin, which remains stable for several
days, is a useful alternative to vasopressin measurements and will likely facilitate the differential
diagnosis of disorders of water metabolism. (J Clin Endocrinol Metab 96: 1046–1052, 2011)
The antidiuretic hormone, arginine vasopressin (AVP),is a nonapeptide hormone synthesized in the magno-
and parvocellular neurons of the paraventricular and su-
praoptic nuclei of the hypothalamus. It is stored and se-
creted into the bloodstream by the posterior pituitary. By
increasing water permeability of the apical membrane of
renal collecting duct cells, AVP promotes free water re-
absorption and is therefore one of the key regulators of
the body’s water and solute balance (1). A rise in plasma
osmolality above280mOsm/kg is themain stimulus for
AVP release (2). Nonosmotic stimuli include a decrease of
circulating blood volume and low blood pressure (3), as
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well as nausea, vomiting, pain, various drugs, and insulin-
induced hypoglycemia (4).
AVP is synthesized as prepro-hormone and consists of
a signal peptide, theAVPandneurophysin IImoieties, and
a C-terminal peptide of 39 amino acids, termed copeptin,
that contains a single N-linked glycosylation site (5, 6)
(Fig. 1). In neurosecretory granules, the hormone precur-
sor is proteolytically processed to yield AVP, neurophysin
II, and copeptin, which are cosecreted from the posterior
pituitary. The plasma half-life of AVP is short (24 min)
(7) and similar to that of copeptin (8, 9). The physiological
role of copeptin is unknown.
Determination of plasma AVP concentrations is
helpful for the differential diagnosis of disorders in-
volving sodium abnormalities, including the various
subtypes of the syndrome of inappropriate antidiuretic
hormone secretion and partial forms of both neurohy-
pophyseal and renal diabetes insipidus (10, 11). How-
ever, reliable measurement of plasma AVP is challeng-
ing and time-consuming, and validated AVP assays are
therefore scarce (12). More than 90% of circulating
AVP is bound to platelets, resulting in either underes-
timation or, in case of prolonged storage of unprocessed
blood samples at room temperature, falsely elevated
AVP levels (13). As a consequence of these technical
drawbacks and the paucity of reliable commercially
available AVP assays, measurement of circulating AVP
levels is not usually part of clinical routine diagnostics.
UnlikeAVP, copeptin remains stable ex vivo for several
days at room temperature in serum or plasma. A sensitive
sandwich immunoassay for the detection of copeptin in
human serum or plasma has recently been developed (8),
offering a potential alternative to available AVP assays.
However, as of yet, the assay has mainly been used in the
evaluation of copeptin as biomarker (14). Elevated levels
of AVP and copeptin have been found in critically ill
patients with the systemic inflammatory response syn-
drome and sepsis (15, 16), in hemorrhagic and septic
shock (9), and in trauma patients (17). Copeptin may be
prognostically meaningful; high circulating copeptin
levels have been found to predict the outcome in ad-
vanced heart failure (18, 19), after myocardial infarc-
tion (20–22), in community-acquired pneumonia (23),
as well as in stroke (24), and may indicate long-term
clinical failure after acute exacerbation of chronic ob-
structive pulmonary disease (25).
Dataon thephysiological changes of copeptin levels are
scarce. A clinical study indicated that circulating copeptin
concentrations reflect posterior pituitary integrity in pa-
tients undergoing insulin-induced hypoglycemia for eval-
uation of anterior pituitary function (26). Another study
evaluatedhealthy volunteers in various states of hypo- and
hyperosmolality and found that copeptin concentrations
correlatedwell with plasma osmolality (27, 28); however,
AVP levels were not reported because of the lack of a
reliable assay. Also, no data on urine osmolalities were
reported, which is a crucial parameter reflecting AVP ac-
tion at the target organ. Therefore, important information
on copeptin as a surrogate for AVP is still lacking. In par-
ticular, no data are available on the correlation between
circulating levels of AVP and copeptin. In case of a close
correlation of the two parameters, the measurement of
copeptin might serve as a surrogate marker for AVP,
thereby superseding the problematic AVP assays.
Materials and Methods
Study subjects
The studywas performed in 20 healthy volunteers (8men, 12
women) 18 yr of age. Exclusion criteria included a history or
presence of heart failure, liver cirrhosis or chronic alcohol con-
sumption, nephrotic syndrome, renal failure (defined as a cal-
culated creatinine clearance100ml/min), anemia (hemoglobin
concentration100 g/liter), uncontrolled hypertension (systolic
blood pressure 160 mm Hg, diastolic blood pressure 95
mm Hg), and other severe disease. Subjects with hypo- or hy-
perthyroidism,hypo-orhypercortisolism,knowndipsomaniaor
diabetes insipidus, pregnancy, or lactation were ineligible. All
female subjects were investigated during the follicular phase of
themenstrual cycle, when the osmotic threshold for AVP release
is similar in men and women (29).
Study procedures
The study was approved by the local review board and reg-
istered (www.ClinicalTrials.gov number, NCT00696605).
Written informed consent was obtained from all study subjects.
One week before the test, each subject underwent a clinical and
laboratory evaluation, which included a medical history, phys-
ical examination, fasting standard blood tests (blood count, cre-
atinine, bloodureanitrogen, glucose, total protein, albumin, and
electrolytes), plasma and urine osmolality, TSH (normal values,
0.4 to 4mU/liter), and cortisol before and after stimulation with
250g tetracosactide (Synacthen;Novartis Pharma, Basel, Swit-
zerland) iv (a normal adrenal functionwas defined as at least one
cortisol value550nM). Subjectswere then scheduled foranoral
water load-hypertonic iv saline test (12). For 12 h before the test,
they refrained from smoking and drinking caffeinated or alco-
AVPSP NP II Copeptin
Prepro-Vasopressin
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FIG. 1. Schematic structure of the vasopressin prepro-hormone
consisting of the signal peptide (SP), the vasopressin hormone (AVP),
the carrier protein neurophysin II (NPII), and the glycoprotein copeptin,
where the glycan is represented by a diamond. The numbers denote
the amino acids present in each moiety.
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holic beverages but had access to ad libitum fluids. Approxi-
mately 2 h before the test, they had a light breakfast. The testwas
performed in recumbent position. Before administering the wa-
ter load, a separate angiocath was placed in each arm of the
subjects for blood draws and for the 3% saline infusion, respec-
tively. All blood samples drawn during the test were centrifuged
immediately for 10min. at 1500 g in a cooled table centrifuge.
Plasma was carefully separated from cells using plastic pipettes,
and plasma aliquots were rapidly transported on ice to a20 C
freezer, where theywere stored for later copeptin andAVPbatch
analyses. PlasmaAVPwasmeasured byRIA as described (12). The
coefficient of variationof the assaywas11.9%(lowrange) to6.4%
(highrange).ThestandardcurvewasobtainedusingunlabeledAVP
(FerringPharmaceuticals,Parsippany,NJ).Thecurvewasverysim-
ilar to curves obtained with the same stock in earlier assays, con-
firming adequate labeling of the AVP tracer. Copeptin was mea-
sured in a blinded fashion in a single batch with a commercial
sandwich immunoluminometric assay (B.R.A.H.M.S LUMItest
CT-proAVP, B.R.A.H.M.S AG, Hennigsdorf/Berlin, Germany)
as described previously (8). Since this initial publication, the as-
say was modified as follows: The capture antibody was replaced
by a murine monoclonal antibody directed to amino acids 137–
144 (GPAGAL) of proAVP.Thismodification improved the sen-
sitivityof the assay.The lowerdetection limitwas0.4pM, and the
functional assay sensitivity (20% interassay coefficient of vari-
ation) was 1 pM (30). The intraassay coefficient of variation
was 10%. In 359 healthy individuals (153 men and 206
women), median copeptin values were 4.2 pmol/liter (range,
1–13.8 pmol/liter; 95% confidence interval, 4.0–4.4 pmol/liter)
(8).Atall timepoints,urineandplasmaosmolalitiesweremeasured
immediately after obtaining the samples on an Advanced Instru-
ments 3320Osmometer by freezing point depression. The intraas-
say coefficient of variation was0.7% for osmolalities in the low
(300 mOsm/kg), intermediate (500 mOsm/kg), and high (700
mOsm/kg) ranges, respectively. The interassay coefficients of vari-
ationwere1.3%for the low,1%for the intermediate, and1.6%for
thehigh range, respectively.ElectrolytesweremeasuredonaRoche
Integra 800 analyzer. As a control, plasma osmolalities were cal-
culatedusingtheformula:osmolality2 [Na] [Gluc] [BUN]
(all values in mM).
For the water load, subjects drank 20 ml/kg body weight of
tap water within 30 min. Every 30 min after starting the test,
blood and urine samples were collected. Concurrently, blood
pressure and heart rate were recorded, and thirst perceptionwas
rated on a scale from1 to 10. Thesemeasurementswere repeated
until urine osmolality had dropped to 100 mOsm/kg or until
120 min after beginning of the test, whichever occurred first.
Subsequently, administration of 3% saline infusion was started
at a rate of 0.1 ml  kg body weight1  min1. Every 20 min
during the infusion, blood samples were drawn and thirst per-
ception was recorded. The infusion was stopped when plasma
osmolality had reached300 mOsm/kg for the first time. Urine
samples, if available, were collected and analyzed in parallel to
blood.At the end of the infusion, blood and urinewere collected.
Subjects were then allowed to drink and eat. One and 2 h after
the end of the infusion, blood and urine samples were again
collected and analyzed.
Statistical analysis
Experimental data from three subjects were excluded from
analysis because of technical issues. Thus, complete matched
data from 17 individuals were available for analysis. Osmolal-
ities and copeptin concentrations were compared across time
points using repeatedmeasuresANOVA.Pairwisepost hoc com-
parisonswere performedusing the paired t test. Spearman’s rank
correlation coefficients were calculated to correlate the follow-
ing parameters: plasma osmolality and AVP concentration;
plasma osmolality and copeptin concentration; plasmaAVP and
copeptin concentrations; plasma copeptin concentration and
urine osmolality; plasma copeptin concentration and thirst per-
ception. Because these correlation coefficients involve repeated
measurements in each subject, no P values were calculated. To
assess temporal correlations of different parameters within sub-
jects, rank correlation coefficients were computed for each pair
of parameters and each subject. Confidence limits of their me-
dians were determined in the standard nonparametric way. All
tests performed were two-tailed, and statistical significance was
defined at a level of 5%.
Results
The baseline characteristics of the 20 subjects participat-
ing in the study are shown in Table 1. All had uneventful
medical histories and normal findings on physical exam-
ination and laboratory evaluation, including thyroid and
adrenal function.
Immediately before the water load (time point t-1),
median plasma osmolality was 290 mOsm/kg (range,
284–302); plasma AVP 1.84 pM (0.46–15.7); plasma
copeptin 3.3 pM (1.1–36.4); and urine osmolality 874
mOsm/kg (219–1141). Figure 2A depicts plasma os-
molalities throughout the waterload/hypertonic saline
test as box-whisker plots. Median plasma osmolality
decreased significantly from 290 mOsm/kg (at time
point t-1) to 281 mOsm/kg after water load (range,
273–288). After 3% saline infusion, a peak median os-
molality of 301mOsm/kg (range, 298–307) was reached,
a significant increase compared with the values of the pre-
vious time points. Changes of plasma copeptin concen-
trations during the test are shown in Fig. 2B. Median val-
ues decreased from 3.3 pM at time point t-1 to 2.0 pM
(range, 0.9–10.4) after water load and increased to 13.6
pM (range, 3.7–43.3) after hypertonic saline.MedianAVP
concentrations changed similarly during the course of the
test [data not shown; t-1, 1.84 pM (range, 0.46–15.7);
after water load, 1.29 pM (range, 0.46–14.1); after hyper-
tonic saline, 5.07 pM (range, 1.8–46.8)].
TABLE 1. Baseline characteristics of study subjects
Age (yr) 30.3  8.7
Male (n) 8
Female (n) 12
Body mass index (kg/m2) 21.9  2.88
Plasma 	Na
 (mM) 138.3  1.72
Plasma osmolality (mOsm/kg) 289.6  6.12
Plasma glucose (mM) 4.8  0.48
Plasma creatinine (M) 71.8  13.07
Values are given as means  SD, where appropriate.
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We correlated plasma osmolalities of all time points
of the test with corresponding copeptin and AVP con-
centrations. As shown in Fig. 3, plasma AVP and co-
peptin concentrations at a given osmolality varied
widely between individuals, particularly at osmolalities
above 285 mOsm/kg. Nevertheless, the correlations
were close [Spearman’s rank correlation coefficient (rS)
0.49 for correlation between osmolality and AVP and
0.77 between osmolality and copeptin, respectively].
Figure 4 shows the corresponding vasopressin and copep-
tin values of all time points of the test. The parameters are
strongly correlated with a rS of 0.8. The median rS was
significantly larger than 0 (P  0.0001 by the sign test;
data not shown). We also analyzed intersubject correla-
tions between vasopressin and copeptin across all time
points of the water load-hypertonic saline test. The min-
imal observed rSwas 0.57 (P 0.07; 90min. after starting
the administration of the oral water load), the maximal rS
was 1.0 (observed at 180min. after starting the 3% saline
infusion). In addition, we calculated individual rank cor-
relations between AVP and plasma osmolality as well as
copeptin and plasma osmolality. Median rS for AVP and
plasma osmolality was 0.64 (interquartile range, 0.52–
FIG. 4. Scatter plot of all plasma AVP and copeptin concentrations
measured during the individual water load-hypertonic saline tests. rS
denotes the Spearman’s rank correlation coefficient.
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FIG. 2. The distributions of measured plasma osmolalities (A) and
plasma copeptin concentrations (B) are shown as box and whisker
plots immediately before starting the water load-hypertonic saline test
(t-1); after ingestion of 20 ml/kg body weight (water load), and after
the infusion of hypertonic saline at 0.1 ml  kg body weight1  min1
(3% saline), as described in the text. The lower and upper edges of the
boxes represent the 25th and 75th percentiles, respectively, whereas
the horizontal line inside the box indicates the median. Values whose
distance to the box exceeds 1.5 times the interquartile range are
displayed as individual points.
FIG. 3. Plasma AVP and copeptin concentrations measured during the
individual water load-hypertonic saline tests are shown as scatter plot.
rS denotes Spearman’s rank correlation coefficients.
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0.79); median rS for copeptin and plasma osmolality was
0.91 (interquartile range, 0.88–0.95). We correlated
plasma copeptin concentrations with urine osmolalities
and thirst perception. The Spearman correlation coeffi-
cients (rS)were 0.38 and0.55, respectively, indicating that
circulating copeptin levels reflect the activity of the thirst
mechanism aswell as the antidiuretic effect of vasopressin
at the level of the target organ.
Discussion
Copeptin, the C-terminal glycopeptide domain of prova-
sopressin, is cosecreted with AVP from the posterior pi-
tuitary in hyperosmolar states (28) and upon multiple
nonosmotic stimuli, such as hypotension, pain, and other
nonspecific causes of stress.Circulating copeptin levels are
therefore believed to reflect the activity of the neuroendo-
crine stress axis, and copeptin has increasingly been prop-
agated as prognostically useful biomarker in a variety of
acute illnesses (14). In a study with multiple trauma pa-
tients, plasma concentrations of copeptin and AVP cor-
related strongly (17). In addition to its prognostic value,
copeptin could serve as diagnostic parameter in the differ-
ential diagnosis of hyponatremia. Recently, it has been
shownthat the ratioofplasmacopeptin tourine sodiummay
be used to differentiate between hyponatremia in the syn-
drome of inappropriate antidiuresis (ratio30 pmol/mmol)
and hyponatremia attributable to edema-forming states or
extrarenal sodium loss (ratio 30 pmol/mmol); further-
more, a suppressed circulating copeptin level ( 3 pM) in the
presence of an intact free water clearance (urine osmolality
200 mOsm/kg) may identify patients with primary poly-
dipsia (30). For many years, AVP has been used to differ-
entiate between all types of diabetes insipidus, including
partial forms and primary polydipsia (10). However, the
reliablemeasurement ofAVP inplasma is time-consuming
and technically demanding. Commercially available AVP
assays validated for clinical routine are scarce. Thus, the
recent development of a copeptin chemoluminescence
sandwich immunoassay (8) may constitute a valuable al-
ternative to the AVP RIA (12) when evaluating disorders
of water and sodium homeostasis. To establish this, the
correlation of circulating copeptin and AVP levels should
be known. We therefore measured, for the first time, co-
peptin and AVP plasma concentrations simultaneously in
healthy subjects during isoosmolar as well as hypo- and
hyperosmolar conditions induced by a water load or hy-
pertonic saline infusion.
We noted considerable variations of copeptin levels at
the start of the tests, most likely representing the lack of a
defined steady-state at baseline in terms of hydration and
osmoregulation. One study subject showed a maximum
value of 36.4 pM, which is above the 99th percentile of
18.9 pM found in a large reference population (31). In this
individual, we cannot exclude the presence of a nonos-
motic stimulus for AVP/copeptin secretion, although this
was clinically not evident.
As expected, both plasma AVP and copeptin concen-
trations correlated with plasma osmolality (Fig. 3), al-
though in the case of AVP the correlation was less close.
There were some instances where measured AVP levels,
relative to the plasma osmolalities, were lower than could
be expected from published data (Fig. 3). To account for
possible technical difficulties with the measurement of
plasma osmolalities, we calculated plasma osmolalities
and correlated them with the measured osmolalities and
the hormone values.We founda close correlationbetween
measured and calculated plasma osmolalities (rS 0.84).
Calculated osmolalititieswere somewhat lower thanmea-
sured values by 4.3  5.3 (mean  SD) mOsm/kg, but
overall, rank correlations (rS) of AVP and copeptin con-
centrations with calculated osmolalities (0.45 and 0.72,
respectively) were similar to those with measured osmo-
lalities (0.49 and 0.77, respectively). One possible expla-
nation for the relatively low AVP levels found in some
individuals is that although the osmotic threshold and sen-
sitivity of AVP secretion are highly reproducible in a given
individual, their interindividual variation is quite large
(32).Rarely, the osmotic threshold forAVP releasemaybe
as high as 290 mOsm/kg or more. Theoretically, we can-
not completely exclude that falsely low AVP concentra-
tions may have resulted in some instances from improper
handling of the plasma samples in the preanalytical phase,
particularly during transport. During the water load-hy-
pertonic saline tests, we took every possible precaution
while obtaining the samples. Samples were drawn on ice,
centrifuged in a cooled table centrifuge, frozen immedi-
ately, and shipped by a courier on dry ice without prior
thawing. The complexity and potential methodological
drawbacks of the AVP RIA, including potentially long
shipping time of samples and the fact that standard ref-
erence material for AVP is not available, underscore the
need for a reliable substitute for routine clinical practice.
The copeptin sandwich immunoluminometric assayoffers
such an alternative, yielding results to the clinician within
hours (8).
Our study has some limitations. The mean age of the
studied individuals was30 yr (30.3 8.7 yr), therefore
our results may not be generalizable to children or to an
older population. Also, because we studied healthy indi-
viduals, we cannot extend our findings to patients with
potentially interfering conditions such as impaired renal
function. While the half-life of copeptin in healthy indi-
viduals is similar toAVP (as seen by the fast decline during
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thewater load-hypertonic saline test), it is yet unclear how
copeptin is removed from the circulation. Like AVP, co-
peptin seems to be at least partially cleared via the kidneys,
as it is detectable in the urine (N.G. Morgenthaler, un-
published). Hence, the clearancemay be impaired in renal
disease (16). Furthermore, in acutely ill patients, the se-
cretionofAVPandcopeptinmaybepredominantly driven
by nonosmotic stimuli, and plasma concentrations do not
reflect osmoregulation (33). In this setting, the role of co-
peptin in the analysis of electrolyte disturbances needs to
be established in further studies.
In summary, the results presented here document a
close correlation between plasma AVP and copeptin con-
centrations across a wide range of plasma osmolalities in
healthy individuals. These findings indicate that copeptin
can indeed be used as a surrogate for AVP release. This
observation has important clinical implications because it
suggests that the measurement of copeptin may be a suit-
able alternative to the technically challenging AVP assay.
In the future, establishing the ranges of stimulated copep-
tin concentrations in patients with complete and partial
forms of neurohypophyseal and renal diabetes insipidus,
as previously done for AVP (10), are expected to facilitate
the correct diagnosis in these patients.
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